Table 5.
Management of children with HBoV infection divided into the two groups.
| Treatment | Total (n = 165) | Group A (n = 69) | Group B (n = 96) | p-Value |
|---|---|---|---|---|
| ARS, n (%) | 9 (5.4) | 0 | 9 (9.4) | 0.005 |
| HHHFNC, n (%) | 24 (14.6) | 12 (17.4) | 12 (12.5) | 0.536 |
| LFN Oxygen therapy, n (%) | 23 13.9) | 11 (16.9) | 12 (12.5) | 0.621 |
| Inhaled SABA, n (%) | 73 (44.2) | 35 (50.7) | 38 (39.6) | 0.155 |
| Antibiotics, n (%) | 80 (48.5) | 29 (42) | 51 (53) | 0.160 |
ARS: advanced respiratory support; C-PAP: continuous positive airway pressure; HHHFNC: Heated Humidified High-Flow Nasal Cannula; LFN: low flow nasal; SABA: Short-Acting Beta-Agonist.